With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.192130-34-0,tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (278 mg, 0.82 mmol), tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate (281 mg, 1.23 mmol) and K2C03 (226 mg, 1.64 mmol) in DMF (1 mL) was heated at 100¡ãC for l8hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x 3). The combined organic layers were washed by water (10 mL x 3) and brine (10 mL), dried over Na2SO4. Filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified prep-TLC to afford tert-butyl 4-(2-(2-(4- (diethylcarbamoyl)phenyl)- 1 ,6-naphthyndin-4-ylamino)ethyl)piperazine- 1 -carboxylate (90 mg, 20percent). LC-MS (ESI): 533.3(M + 1)., 192130-34-0
As the paragraph descriping shows that 192130-34-0 is playing an increasingly important role.
Reference£º
Patent; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; PINKERTON, Anthony B.; ARDECKY, Robert J.; ZOU, Jiwen; (256 pag.)WO2018/204176; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics